Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: a systematic review and reconstructed patient-data meta-analysis
Tumor DNA in blood changes its ability to predict outcomes over time, suggesting when and how to use it matters for cancer monitoring.
This PubMed-indexed meta-analysis examines Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: a systematic review and reconstructed patient-data meta-analysis. The available abstract reports Circulating tumor DNA (ctDNA) increasingly guides adjuvant therapy and surveillance in urothelial carcinoma (UC), yet whether its prognostic effect is adequately summarized by a single pooled hazard ratio (HR), which assumes proportional hazards (PH), has not been formally evaluated We searched five sources for.
What the study was
- Study design
- Meta-analysis
- Population
- Human participants
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Critical reviews in oncology/hematology
Why it surfaced
Conservative rapid triage: meta-analysis, human evidence, and direct relevance to Early cancer detection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.